At a glance
ClinicalIndex Comparison Record- ✓Age ≥18 years
- ✓Genotype-confirmed CXCR4 mutation consistent with WHIM syndrome
- ✓Confirmed ANC ≤400/µL or ALC ≤650/µL or both
- ✓Willing and able to comply with protocol
- ✕Known hypersensitivity to mavorixafor or its inactive ingredients
- ✕Pregnant or nursing
- ✕Known HIV infection or AIDS
- ✕Hepatitis C antibody positive unless documented undetectable viral load on 2 independent samples
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open-Label, Multi-Center Trial of Mavorixafor in Patients With WHIM Syndrome
In Brief
A Phase 2 clinical trial evaluating X4P-001 for WHIM Syndrome. Completed, enrolled 8 participants across 2 sites in 2 countries.
Detailed Summary
This is a Phase 2 study with an initial 24-week Treatment Period and an Extension Phase. The primary objectives of this Phase 2 study are to determine the safety, tolerability, and dose selection of mavorixafor in participants with WHIM syndrome. Participants may continue treatment in an Extension Phase, if regionally applicable, until mavorixafor becomes available via an alternative mechanism (for example, drug is commercially available, an expanded access program, etc.) or until the study is terminated by the Sponsor for any reason.
Study Details
Timeline
Interventions
Mavorixafor will be provided as either 25 mg or 100 mg capsules.